Artivion (NYSE:AORT) Sets New 1-Year High – What’s Next?

Artivion, Inc. (NYSE:AORT) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $29.77 and last traded at $29.77, with a volume of 23143 shares trading hands. The stock had previously closed at $27.89.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AORT shares. Stifel Nicolaus boosted their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. JMP Securities initiated coverage on Artivion in a research report on Wednesday, October 23rd. They issued an “outperform” rating and a $33.00 price target on the stock. Finally, Oppenheimer upped their price objective on Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $30.60.

Artivion Stock Performance

The stock’s 50-day moving average is $26.16 and its 200 day moving average is $25.06. The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. The firm has a market cap of $1.21 billion, a P/E ratio of -138.00 and a beta of 1.75.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. The firm had revenue of $98.02 million during the quarter, compared to the consensus estimate of $97.70 million. On average, research analysts predict that Artivion, Inc. will post 0.2 earnings per share for the current year.

Insider Activity

In related news, Director Anthony B. Semedo sold 9,709 shares of Artivion stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the sale, the director now directly owns 34,159 shares of the company’s stock, valued at approximately $853,633.41. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Anthony B. Semedo sold 9,709 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total value of $242,627.91. Following the completion of the transaction, the director now owns 34,159 shares of the company’s stock, valued at $853,633.41. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Matthew A. Getz sold 9,420 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the transaction, the vice president now owns 34,116 shares of the company’s stock, valued at $863,475.96. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,109 shares of company stock valued at $951,935. 8.10% of the stock is owned by company insiders.

Institutional Trading of Artivion

A number of hedge funds and other institutional investors have recently modified their holdings of AORT. The Manufacturers Life Insurance Company lifted its holdings in shares of Artivion by 3.2% during the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock worth $392,000 after purchasing an additional 481 shares during the period. Louisiana State Employees Retirement System boosted its stake in shares of Artivion by 3.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock valued at $510,000 after purchasing an additional 600 shares during the last quarter. Texas Permanent School Fund Corp increased its position in shares of Artivion by 2.0% during the first quarter. Texas Permanent School Fund Corp now owns 34,129 shares of the company’s stock worth $722,000 after buying an additional 677 shares during the period. nVerses Capital LLC bought a new position in Artivion during the second quarter worth $28,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Artivion by 5.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock valued at $713,000 after buying an additional 1,634 shares during the period. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.